CINCINNATI, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio today for Next-Generation Sequencing (NGS) library preparation.
The new JetSeq Clean Kit is a clean-up system based on paramagnetic bead technology, designed for efficient purification of nucleic acid fragments in the next-generation sequencing workflow. JetSeq Clean removes salts, primers, primer-dimers, and dNTPs; while library fragments are selectively bound to the magnetic particles based on their size, allowing one-sided and two-sided "solid phase reversible immobilization" (SPRI) size selection. Purified library fragments are eluted from the magnetic particles using water or a low salt buffer and can be used directly for all downstream NGS applications.
Marco Calzavara, President of Bioline commented, “We are pleased to announce the release of the new JetSeq Clean Kit. The release of the new JetSeq Clean Kit complements the JetSeq Library preparation and JetSeq Quantification kits, extending our portfolio of high quality products to help researchers with NGS library preparation.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “This is another important addition to our innovative portfolio of NGS products and gives our life science customers greater confidence in the production their sequencing libraries. The continued development of the JetSeq family shows our commitment to the expansion of products from Bioline in this field and continued commitment to our customers, giving them a greater support around this fast-growing field.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:
For more information about Bioline, please visit http://www.bioline.com.
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Meridian Bioscience, Inc.